PMID- 23844818
OWN - NLM
STAT- MEDLINE
DCOM- 20150126
LR  - 20220409
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 20
IP  - 14
DP  - 2014
TI  - Role of AGEs-RAGE system in cardiovascular disease.
PG  - 2395-402
AB  - Advanced glycation end products (AGEs) are a heterogenous group of molecules 
      formed during a non-enzymatic reaction between proteins and sugar residues. 
      Recently, AGEs and their receptor (receptor for AGEs; RAGE) play a central role 
      in the pathogenesis of cardiovascular disease (CVD), which accounts for 
      disability and high mortality rate in patients with diabetes. AGEs initiate 
      diabetic micro- and macrovascular complications through the structural 
      modification and functional alteration of the extracellular matrix proteins as 
      well as intracellular signaling molecules. Engagement of RAGEs with AGEs elicits 
      intracellular reactive oxygen species (ROS) generation and subsequently activates 
      mitogen-activated protein kinase (MAPK) and nuclear factor kappa-B (NF-kappaB) 
      signaling, followed by production of several inflammatory and/or profibrotic 
      factors such as vascular cell adhesion molecule-1 (VCAM-1), intercellular 
      adhesion molecule-1 (ICAM-1), plasminogen activator inhibitor-1 (PAI-1) and 
      monocyte chemoattractant protein-1 (MCP-1), thereby being involved in the 
      progression of atherosclerosis. Administration of soluble form of RAGE (sRAGE) 
      could work as a decoy receptor for AGEs and might inhibit the binding of AGEs to 
      RAGE, preventing the development and progression of atherosclerosis in animal 
      models. Furthermore, AGEs/high mobility group box-1 (HMGB-1)-RAGE interaction is 
      involved in heart failure, abdominal aortic aneurysm (AAA) and vascular 
      calcification as well. Thus, blockade of the AGEs/HMGB-1-RAGE system may be a 
      promising therapeutic target for preventing diabetes- and/or age-related CVD. We 
      review here the pathological role of the AGEs/HMGB-1-RAGE system in various types 
      of CVD.
FAU - Fukami, Kei
AU  - Fukami K
FAU - Yamagishi, Sho-Ichi
AU  - Yamagishi S
FAU - Okuda, Seiya
AU  - Okuda S
AD  - Division of Nephrology Department of Medicine, Kurume University School of 
      Medicine, 67 Asahimachi, Kurume, Fukuoka 830-0011 Japan. 
      fukami@med.kurume-u.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Reactive Oxygen Species)
SB  - IM
MH  - Animals
MH  - Cardiovascular Diseases/etiology/*metabolism
MH  - Glycation End Products, Advanced/*physiology
MH  - Humans
MH  - Reactive Oxygen Species/metabolism
EDAT- 2013/07/13 06:00
MHDA- 2015/01/27 06:00
CRDT- 2013/07/13 06:00
PHST- 2013/05/06 00:00 [received]
PHST- 2013/06/19 00:00 [accepted]
PHST- 2013/07/13 06:00 [entrez]
PHST- 2013/07/13 06:00 [pubmed]
PHST- 2015/01/27 06:00 [medline]
AID - CPD-EPUB-53274 [pii]
AID - 10.2174/13816128113199990475 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2014;20(14):2395-402. doi: 10.2174/13816128113199990475.